KBI is very proud to announce a huge boost to its research service capacity to a new high in 2022. The newly-boosted capacity includes a huge expansion of KBI’s laboratory space and acquisition of the state-of-the-art imaging facilities.
By March 2022, KBI has expanded its laboratory space from about 1000 m2 to 2500 m2. The newly-established 1500 m2 of laboratories will dramatically upgrade our service capacity of molecular and cell biology, pathology, biomarker and imaging.
KBI conducted an annual training of animal operation skills on April 6, 2022. Experts from Yunnan University and Kunming Medical University were invited to share their experience.
The FDA (USA) has recently approved of the clinical trial on the investigational new drug B1344 for the treatment of nonalcoholic steatohepatitis (NASH). https://med.sina.com/article_detail_100_2_111927.html
KBI, Shanghai Institute of Nutrition and Health and Tasly have jointly evaluated the efficacy and safety of B1344 in KBI's monkey model of NASH. The results showed that B1344 is safe and ameliorates all NASH pathology characteristics, particularly hepatic fibrosis. These findings were reported in Diabetes (doi.org/10.2337/db20-0209) where KBI’s NASH model and methods (including pharmacodynamics and pharmacokinetics) were detailed.
This research received an editorial commentary by the invited experts in the field (doi.org/10.2337/dbi20-0025). It is another report in high-impact journals about KBI’s studies on metabolic diseases in monkey models:
The latest issue of Cell Metabolism has published the following research paper which reveal a new triagonist targeting at GLP-1/GIP/GCG receptors for the effective control of body weight and blood glucose (Open access : https://doi.org/10.1016/j.cmet.2021.12.005).
This paper describes the details about the studies in the cynomolgus monkey obesity and diabetes models, research methods and obtained results at Kunming Biomed International (KBI). The study references also include the KBI’s publications about the studies of metabolic disease models in cynomolgus monkeys.
2021 is a very exciting year for KBI with the biggest injection of fresh blood!
With the breakthrough performance and rapid growth of our research services, we have recently recruited 39 new staff members. Our new family members range from university graduates to highly-experienced professionals at the middle and senior levels. They bring in new dynamics, skills and experiences at all levels of KBI, and truly reflect KBI’s values of diversity, merit-based, gender-balanced and equal opportunity.
Kunming Biomed International (KBI) today announced the appointment of Jiming Ye (MD, PhD) as Chief Scientific Officer. Dr. Ye will join company executive team to lead the company’s internal and external drug discovery programs in collaboration with pharmaceutical, biotech as well as academic communities.
Kunming Biomed International (KBI) has previously developed large cohorts of NASH and liver fibrosis models in nonhuman primates (NHPs) mirroring human patient’s disease pathophysiology, clinical progression, and histopathological stages, including steatosis monkeys (n>800), NASH monkeys (n>500) and liver fibrosis monkeys (n>150).
For the upcoming Liver Meeting® 2018 of American Association for the Study of Liver Diseases (AASLD), KBI will present its accomplishments in the development and validation of non-invasive imaging biomarkers such as PDFF and MRI-ECV as well as circulating biomarkers like TIMP-1 for the assessment of hepatic lesions in our NHP model of Nonalcoholic Steatohepatitis (NASH).
Join KBI and more than 9,500 hepatologists and hepatology health professionals from around the world at the annual AASLD conference to be held at the Moscone North and South Convention Center in San Francisco, California on 9-13 November 2018.
Our poster presentation details are below:
Publication Number: 1767
Session Date and Time: Sunday, November 11, 2018, 8:00 AM
Presentation Type: Poster Presentation
Location: Moscone Center North/South Building, Hall C
Our poster presentation details are below:
Poster Board #: SA-PO102
Session Title: Diabetic Kidney Disease: Basic - III [PO0601-3]
Session Date, Time: October 27, 2018 from 10:00 AM to 12:00 PM
Location: Exhibit Hall, San Diego Convention Center
Kunming Biomed International (KBI) announces the hiring of Kaiming Zhang as Head of Eye Diseases. "We welcome Kaiming joining us to strengthen KBI’s capability in metabolic complications such as diabetic retinopathy and establish eye disease technology platform in non-human primates (NHPs). This appointment demonstrates that KBI will continuously enhance the leading position in preclinical services in metabolic diseases and metabolic complications including heart failure, NASH/liver fibrosis, diabetic nephropathy and diabetic retinopathy". In addition, Kaiming’s leadership in this area will facilitate KBI’s quick expansion into other eye disease related to aging”, said Dr. Bob Zhang, CEO of KBI.
Kunming Biomed International (KBI) announces the hiring of Zhiming Ding, MD, Ph.D, as Chief Scientific Officer. "We welcome Zhiming joining our executive management team to further strengthen company's core competence in translational non-human primate (NHP) models in metabolic, cardiovascular and NASH/fibrosis spaces. Appointment of Dr. Ding reflects KBI's continuous commitment and dedication to providing high quality and science-based preclinical services, ultimately translating preclinical potential into clinical success to our collaborators", said Dr. Bob Zhang, CEO of KBI.
Dr. Zhiming Ding brings to KBI over 30 years' experience in biomedical field including 17 years in drug discovery. He has strong expertise in cardiovascular and metabolic diseases and extensive experience in project management and execution. He is the former Research Director and Head of in vivo pharmacology at Lilly China Research Center. He also served at Lexicon Pharmaceutical in the US as the Director of Cardiology/Metabolism. Dr. Ding received his MD and PhD in Toxicology from Tongji Medical University. He had his postdoctoral training at University of Texas at Austin and did research fellow at M.D. Anderson Cancer Center and Baylor College of Medicine.